Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer

Journal of Nuclear Medicine

Volumn 55, Issue 12, 2014, Pages 2050-2056

  Chatalic, Kristell L S ^a   Franssen, Gerben M ^b   Van Weerden, Wytske M ^a   McBride, William J ^c   Laverman, Peter ^b   De Blois, Erik ^a   Hajjaj, Bouchra ^d   Brunel, Luc ^d   Goldenberg, David M ^c   Fehrentz, Jean Alain ^d   Martinez, Jean ^d   Boerman, Otto C ^b   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c IMMUNOMEDICS INC   (United States)

^d CNRS   (France)

Author keywords

18F; Bombesin; GRPR; PET; Prostate cancer

Indexed keywords

ALUMINUM; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GASTRIN RELEASING PEPTIDE DERIVATIVE; GASTRIN RELEASING PEPTIDE RECEPTOR ANTAGONIST; JMV4168 GALLIUM 68 TRACER; JMV5132 ALUMINUM FLUORODEOXYGLUCOSE F 18 TRACER; JMV594 TRACER; TRACER; UNCLASSIFIED DRUG; 68GA-JMV4168; 68GA-JMV5132; AL18F-JMV5132; ALUMINUM DERIVATIVE; ALUMINUM FLUORIDE; BOMBESIN RECEPTOR; COORDINATION COMPOUND; FLUORIDE; FLUORINE; GALLIUM; PEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; CHEMICAL STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EX VIVO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; COMPARATIVE STUDY; DIAGNOSTIC USE; HUMAN; PROCEDURES; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; WHOLE BODY IMAGING;

ALUMINUM COMPOUNDS; ANIMALS; CELL LINE, TUMOR; COORDINATION COMPLEXES; FLUORIDES; FLUORINE RADIOISOTOPES; GALLIUM RADIOISOTOPES; HUMANS; MALE; MICE; MICE, INBRED BALB C; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 84915756742     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141143     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167:2435-2439.
3. Talab SS, Preston MA, Elmi A, Tabatabaei S. Prostate cancer imaging: what the urologist wants to know. Radiol Clin North Am. 2012;50:1015-1041.
4. Mari Aparici C, Seo Y. Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med. 2012;42:328-342.
5. Sancho V, Di Florio A, Moody TW, Jensen RT. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv. 2011;8:79-134.
6. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31:144-154.
7. 14] bombesin(6-14). Clin Cancer Res. 2002;8:1139-1146.
8. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostatespecific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101-1108.
9. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
10. Beer M, Montani M, Gerhardt J, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318-325.
11. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318-326.
12. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15:5240-5249.
13. Basso N, Lezoche E, Speranza V. Studies with bombesin in man. World J Surg. 1979;3:579-585.
14. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging. 2007;34:S221.
15. Llinares M, Devin C, Chaloin O, et al. Syntheses and biological activities of potent bombesin receptor antagonists. J Pept Res. 1999;53:275-283.
16. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
17. Abiraj K, Mansi R, Tamma ML, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011;52:1970-1978.
18. Varasteh Z, Velikyan I, Lindeberg G, et al. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. Bioconjug Chem. 2013;24:1144-1153.
19. 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867-872.
20. 68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434-5443.
21. 11C] choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17:3751-3759.
22. 1H-MR spectroscopy. J Nucl Med. 2010;51:1676-1683.
23. Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55-62.
24. 18F radiolabeling for PET. J Nucl Med. 2009;50:991-998.
25. 111In-labeling, and preclinical profile. J Med Chem. 2013;56:2374-2384.
26. 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22:1793-1803.
27. 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem. 2012;23:1712-1717.
28. 18F-labeled bombesin analog. J Nucl Med. 2012;53:947-952.
29. de Blois E, Chan HS, Breeman WA. Iodination and stability of somatostatin analogues: comparison of iodination techniques: a practical overview. Curr Top Med Chem. 2012;12:2668-2676.
30. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441.
31. Liu Y, Hu X, Liu H, et al. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. J Nucl Med. 2013;54:2132-2138.
32. 18F-labeled high affinity nota conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. PLoS ONE. 2013;8:e81932.
33. McBride WJ, D'Souza CA, Karacay H, Sharkey RM, Goldenberg DM. New lyophilized kit for rapid radiofluorination of peptides. Bioconjug Chem. 2012;23:538-547.
34. Disselhorst JA, Brom M, Laverman P, et al. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med. 2010;51:610-617.